O	0	4	Risk
O	5	12	factors
O	13	16	for
O	17	31	bisphosphonate
O	31	32	-
O	32	42	associated
B-condition	43	56	osteonecrosis
I-condition	57	59	of
I-condition	60	63	the
I-condition	64	67	jaw
O	68	70	in
O	71	74	the
O	75	86	prospective
O	87	97	randomized
O	98	103	trial
O	104	106	of
B-intervention	107	115	adjuvant
I-intervention	116	131	bisphosphonates
O	132	135	for
O	136	141	early
O	141	142	-
O	142	147	stage
O	148	154	breast
O	155	161	cancer
O	162	163	(
O	163	167	SWOG
O	168	172	0307
O	172	173	)
O	173	174	.

O	175	190	Bisphosphonates
O	191	197	reduce
O	198	202	bone
O	203	213	metastases
O	214	216	in
O	217	231	postmenopausal
O	232	237	women
O	238	242	with
O	243	248	early
O	248	249	-
O	249	254	stage
O	255	261	breast
O	262	268	cancer
O	269	272	but
O	273	278	carry
O	279	282	the
O	283	287	risk
O	288	290	of
O	291	305	bisphosphonate
O	305	306	-
O	306	313	related
O	314	327	osteonecrosis
O	328	330	of
O	331	334	the
O	335	338	jaw
O	339	340	(
O	340	345	BRONJ
O	345	346	)
O	346	347	.

O	348	350	We
O	351	359	describe
O	360	364	risk
O	365	372	factors
O	373	376	for
O	377	382	BRONJ
O	383	386	and
O	387	394	compare
O	395	400	BRONJ
O	401	409	provoked
O	410	412	by
O	413	422	infection
O	423	425	or
O	426	432	trauma
O	433	437	with
O	438	449	spontaneous
O	450	457	lesions
O	457	458	,
O	459	464	which
O	465	470	carry
O	471	472	a
O	473	479	better
O	480	489	prognosis
O	489	490	.

O	491	495	SWOG
O	496	500	0307
O	501	511	randomized
B-eligibility	512	517	women
I-eligibility	518	522	with
I-eligibility	523	528	stage
I-eligibility	529	530	I
I-eligibility	530	531	-
I-eligibility	531	534	III
I-eligibility	535	541	breast
I-eligibility	542	548	cancer
O	549	551	to
O	552	559	receive
O	560	570	zoledronic
O	571	575	acid
O	576	577	(
O	577	579	ZA
O	579	580	)
O	580	581	,
O	582	592	clodronate
O	593	594	(
O	594	596	CL
O	596	597	)
O	597	598	,
O	599	601	or
O	602	613	ibandronate
O	614	615	(
O	615	617	IB
O	617	618	)
O	619	622	for
O	623	624	3
O	625	630	years
O	630	631	,
O	632	643	implemented
O	644	649	BRONJ
O	650	660	prevention
O	661	671	guidelines
O	671	672	,
O	673	676	and
O	677	686	collected
O	687	698	information
O	699	704	about
O	705	711	dental
O	712	718	health
O	719	722	and
O	723	734	development
O	735	737	of
O	738	743	BRONJ
O	743	744	.

O	745	748	All
O	749	760	statistical
O	761	766	tests
O	767	771	were
O	772	775	two
O	775	776	-
O	776	781	sided
O	781	782	.

O	783	785	Of
B-total-participants	786	790	6018
O	791	796	women
O	796	797	,
O	798	800	48
B-outcome	801	810	developed
I-outcome	811	816	BRONJ
O	816	817	.

B-outcome	818	827	Infection
O	828	831	was
O	832	839	present
O	840	842	in
O	843	845	21
O	846	847	(
O	847	849	43
O	849	850	.
O	850	851	8
O	851	852	%
O	852	853	)
O	853	854	.

B-outcome	855	861	Median
I-outcome	862	866	time
I-outcome	867	869	to
I-outcome	870	875	BRONJ
O	876	879	was
O	880	881	2
O	881	882	.
O	882	883	1
O	884	889	years
O	890	893	for
O	894	896	ZA
O	896	897	,
B-iv-cont-median	898	899	2
I-iv-cont-median	899	900	.
I-iv-cont-median	900	901	0
I-iv-cont-median	902	907	years
O	908	911	for
O	912	914	IB
O	914	915	,
O	916	919	and
B-iv-cont-median	920	921	3
I-iv-cont-median	921	922	.
I-iv-cont-median	922	923	4
I-iv-cont-median	924	929	years
O	930	933	for
O	934	944	clodronate
O	945	946	(
O	946	947	p
O	948	949	=
O	950	951	0
O	951	952	.
O	952	954	04
O	954	955	)
O	955	956	.

B-outcome	957	962	BRONJ
O	963	966	was
O	967	977	associated
O	978	982	with
O	983	997	bisphosphonate
O	998	1002	type
O	1003	1004	(
B-iv-bin-abs	1004	1006	28
O	1006	1007	/
B-intervention-participants	1007	1011	2231
O	1012	1013	(
B-iv-bin-percent	1013	1014	1
I-iv-bin-percent	1014	1015	.
I-iv-bin-percent	1015	1017	26
I-iv-bin-percent	1017	1018	%
O	1018	1019	)
O	1020	1023	for
O	1024	1026	ZA
O	1026	1027	,
B-iv-bin-abs	1028	1029	8
O	1029	1030	/
B-intervention-participants	1030	1034	2235
O	1035	1036	(
B-iv-bin-percent	1036	1037	0
I-iv-bin-percent	1037	1038	.
I-iv-bin-percent	1038	1040	36
I-iv-bin-percent	1040	1041	%
O	1041	1042	)
O	1043	1046	for
O	1047	1049	CL
O	1049	1050	,
B-iv-bin-abs	1051	1053	12
O	1053	1054	/
B-intervention-participants	1054	1058	1552
O	1059	1060	(
B-iv-bin-percent	1060	1061	0
I-iv-bin-percent	1061	1062	.
I-iv-bin-percent	1062	1064	77
I-iv-bin-percent	1064	1065	%
O	1065	1066	)
O	1067	1070	for
O	1071	1073	IB
O	1073	1074	)
O	1074	1075	,
B-outcome	1076	1082	dental
I-outcome	1083	1091	calculus
O	1092	1093	(
O	1093	1095	OR
O	1096	1097	2
O	1097	1098	.
O	1098	1100	03
O	1100	1101	)
O	1101	1102	,
B-outcome	1103	1113	gingivitis
O	1114	1115	(
O	1115	1117	OR
O	1118	1119	2
O	1119	1120	.
O	1120	1122	11
O	1122	1123	)
O	1123	1124	,
B-outcome	1125	1133	moderate
I-outcome	1133	1134	/
I-outcome	1134	1140	severe
I-outcome	1141	1152	periodontal
I-outcome	1153	1160	disease
O	1161	1162	(
O	1162	1164	OR
O	1165	1166	2
O	1166	1167	.
O	1167	1169	87
O	1169	1170	)
O	1170	1171	,
O	1172	1175	and
B-outcome	1176	1189	periodontitis
I-outcome	1190	1191	>
I-outcome	1192	1193	4
I-outcome	1194	1196	mm
O	1197	1198	(
O	1198	1200	OR
O	1201	1202	2
O	1202	1203	.
O	1203	1205	20
O	1205	1206	)
O	1207	1208	(
O	1208	1209	p
O	1210	1211	<
O	1212	1213	0
O	1213	1214	.
O	1214	1216	05
O	1216	1217	)
O	1217	1218	.

O	1219	1221	Of
O	1222	1224	57
O	1225	1232	lesions
O	1232	1233	,
B-outcome	1234	1239	BRONJ
I-outcome	1240	1248	occurred
I-outcome	1249	1262	spontaneously
O	1263	1265	in
O	1266	1268	20
O	1269	1270	(
O	1270	1272	35
O	1272	1273	.
O	1273	1274	1
O	1274	1275	%
O	1275	1276	)
O	1277	1280	and
O	1281	1284	was
O	1285	1293	provoked
O	1294	1296	by
B-outcome	1297	1303	dental
I-outcome	1304	1314	extraction
O	1315	1317	in
O	1318	1320	20
O	1321	1322	(
O	1322	1324	35
O	1324	1325	.
O	1325	1326	1
O	1326	1327	%
O	1327	1328	)
O	1328	1329	,
B-outcome	1330	1341	periodontal
I-outcome	1342	1349	disease
O	1350	1352	in
O	1353	1355	14
O	1356	1357	(
O	1357	1359	24
O	1359	1360	.
O	1360	1361	6
O	1361	1362	%
O	1362	1363	)
O	1363	1364	,
B-outcome	1365	1372	denture
I-outcome	1373	1379	trauma
O	1380	1382	in
O	1383	1384	6
O	1385	1386	(
O	1386	1388	10
O	1388	1389	.
O	1389	1390	5
O	1390	1391	%
O	1391	1392	)
O	1392	1393	,
O	1394	1397	and
B-outcome	1398	1404	dental
I-outcome	1405	1412	surgery
O	1413	1415	in
O	1416	1417	2
O	1418	1419	(
O	1419	1420	3
O	1420	1421	.
O	1421	1422	5
O	1422	1423	%
O	1423	1424	)
O	1424	1425	.

B-outcome	1426	1437	Spontaneous
I-outcome	1438	1443	BRONJ
O	1444	1452	occurred
O	1453	1457	more
O	1458	1468	frequently
O	1469	1471	at
O	1472	1475	the
O	1476	1485	mylohyoid
O	1486	1491	ridge
O	1491	1492	.

O	1493	1498	There
O	1499	1503	were
O	1504	1506	no
O	1507	1518	differences
O	1519	1521	in
O	1522	1528	dental
O	1529	1536	disease
O	1536	1537	,
O	1538	1547	infection
O	1547	1548	,
O	1549	1551	or
O	1552	1566	bisphosphonate
O	1567	1571	type
O	1572	1579	between
O	1580	1591	spontaneous
O	1592	1595	and
O	1596	1604	provoked
O	1605	1610	BRONJ
O	1610	1611	.

O	1612	1614	ZA
O	1615	1618	and
O	1619	1624	worse
O	1625	1631	dental
O	1632	1638	health
O	1639	1643	were
O	1644	1654	associated
O	1655	1659	with
O	1660	1669	increased
O	1670	1679	incidence
O	1680	1682	of
O	1683	1688	BRONJ
O	1688	1689	,
O	1690	1694	with
O	1695	1696	a
O	1697	1702	trend
O	1703	1709	toward
O	1710	1718	additive
O	1719	1723	risk
O	1724	1728	when
O	1729	1737	combined
O	1737	1738	.

O	1739	1744	BRONJ
O	1745	1754	incidence
O	1755	1758	was
O	1759	1764	lower
O	1765	1769	than
O	1770	1772	in
O	1773	1780	similar
O	1781	1788	studies
O	1788	1789	,
O	1790	1794	with
O	1795	1805	prevention
O	1806	1816	strategies
O	1817	1823	likely
O	1824	1830	linked
O	1831	1833	to
O	1834	1838	this
O	1838	1839	.

O	1840	1851	NCT00127205
O	1852	1864	REGISTRATION
O	1865	1869	DATE
O	1869	1870	:
O	1871	1875	July
O	1876	1880	2005
O	1880	1881	.
